Numerous studies had shown that the HSDL2 was a key factor of fatty acid regulatory in lipid metabolism [14] and abnormal HSDL2 expression was associated with a variety of cancers, such as bladder cancer[15], breast cancer [16], lung adenocarcinoma [17], thyroid carcinoma [18], cholangiocarcinoma [19], ovarian cancer [20], gliomas [21], pancreatic cancer [14] et al. A large number of studies had shown that abnormal lipid metabolism could accelerate/decelerate the progression of CC [22]. This evidence concerns the gene HSDL2 and cholangiocarcinoma.